Variables | Patients with JIA, n = 85 | Controls, n = 46 |
---|---|---|
Male | 20 (25) | 9 (20) |
Age, yrs | 38.6 (35.0–40.6) | 37.7 (34.6–40.4) |
Disease duration, yrs | 29.2 (28.2–30.6) | — |
Onset age, yrs | 8.9 (5.2–11.6) | — |
JIA category distribution | ||
Systemic arthritis | 4 (5) | |
RF-negative polyarthritis | 12 (14) | |
RF-positive polyarthritis | 5 (6) | |
Persistent oligoarthritis | 15 (18) | |
Extended oligoarthritis | 14 (17) | |
Enthesitis-related arthritis | 18 (21) | |
Psoriatic arthritis | 15 (18) | |
Undifferentiated arthritis | 2 (2) | |
Current medication at 29-yr followup | ||
Anti-TNF | 25 (29) | |
Methotrexate | 19 (22) | |
NSAID daily | 23 (27) | |
Prednisolone | 5 (6) | |
Health status in the patients with JIA at 29-yr followup | ||
PGA, 10-cm VAS | 1.5 (0.5–2.4) | |
No. active joints | 1 (0–2) | |
No. joints LROM | 3 (1–7) | |
PtGA, 10-cm VAS | 1.8 (0.7–2.8) |
IQR: interquartile range; JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; anti-TNF: anti-tumor necrosis factor; NSAID: nonsteroidal anti-inflammatory drugs; PGA: physician’s global assessment; VAS: visual analog scale; LROM: limited range of motion; PtGA: patient’s global assessment.